GDC-0834 racemate is primarily investigated for its potential in therapeutic applications, particularly in the field of oncology. It functions as a selective inhibitor of Bruton's tyrosine kinase (BTK), a key enzyme involved in B-cell receptor signaling. By targeting BTK, this compound has shown promise in preclinical studies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Its ability to modulate immune responses also makes it a candidate for autoimmune disease research. Additionally, GDC-0834 racemate is utilized in biochemical studies to better understand BTK signaling pathways and its role in disease progression. Ongoing research aims to optimize its efficacy and explore its potential in combination therapies.